CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-026-05623-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Srividya Arjuna und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 W. Holcombe Blvd., Suite 910, Houston, TX, 7…. Hauptthemen laut MEDLINE: Glioma, Circulating Tumor DNA, Brain Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: There is a critical need for better strategies to diagnose and monitor patients with gliomas. Liquid biopsies are less invasive than tissue biopsies and are amenable to serial collection at multiple timepoints. However, the analysis of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) from patients with gliomas remains underutilized in clinical practice due to technical challenges. METHODS: We collected CSF samples from 43 patients with various types of gliomas and evaluated ctDNA derived from CSF with a next generation sequencing (NGS) panel interrogating 600 cancer-related genes. RESULTS: Total cell-free DNA (cfDNA) concentration obtained from CSF (0.4-5 mL) ranged from 0.09 to 60 ng/µL. Mutations were detected in 26/43 (60%) samples including 19/43 (44%) with single nucleotide variants (SNV), 11/43 (25%) with copy number variants (CNV), 8/43 (18.6%) with frameshifts and 1/43 with fusion (2.3%). Mutations were not identified in 17 CSF samples, and most of these samples (15/17; 88%) had suboptimal DNA input (< 30 ng). We identified diagnostic alterations in CSF including mutations in IDH1 (3/6 IDH-mutant gliomas), TERTp (7/29 glioblastomas), EGFR amplification (5/29 glioblastomas), and H3-3 A (4/4 pediatric high-grade gliomas). Some of these mutations, in combination with other clinical parameters, allowed us to identify specific CNS tumor types based on the 2021 World Health Organization (WHO) classification of CNS tumors, resulting in the reclassification of 3 patients. Furthermore, we observed a significant association between the CSF-ctDNA detection and imaging features. CONCLUSION: This study highlights the potential clinical utility of CSF-ctDNA analysis for evaluating and reclassification of patients with gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 W. Holcombe Blvd., Suite 910, Houston, TX, 77030, USA.
- Department of Neurosurgery, McGovern Medical School at UT Health, Houston, TX, USA.
- Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, USA.
- Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center Houston, Houston, TX, USA.
Förderung
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Arjuna, S., Pirhoushiaran, M., Bueno, A., Sanchez-Espitia, A., Tavakkol, E., Khalaj, K., Shah, M., Wang, I., Balar, A. P., Dono, A., Duose, D., Nguyen, S., Kamali, A., Luthra, R., Patel, C. B., Prabhu, S. S., Lang, F. F., Esquenazi, Y., & Ballester, L. Y. (2026). CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05623-2
Vancouver
Arjuna S, Pirhoushiaran M, Bueno A, Sanchez-Espitia A, Tavakkol E, Khalaj K, et al. CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05623-2
BibTeX
@article{Arjuna2026,
author = {Arjuna, Srividya and Pirhoushiaran, Maryam and Bueno, Angel and Sanchez-Espitia, Alexander and Tavakkol, Elham and Khalaj, Kamand and Shah, Mauli and Wang, Isabel and Balar, Ashish P and Dono, Antonio and Duose, Dzifa and Nguyen, Sophia and Kamali, Arash and Luthra, Rajyalakshmi and Patel, Chirag B and Prabhu, Sujit S and Lang, Frederick F and Esquenazi, Yoshua and Ballester, Leomar Y},
title = {CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-026-05623-2}
}
EUVIMED